VivoSeq
Other

Virus

0

Pipeline Programs

0

Active Trials

3

Companies Involved

Virus is an early-stage landscape with 0 programs across 3 companies. The most active players are Sanofi, Pfizer, Novartis.

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

94/100

Attrition Rate

5/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

37

clinical trials

Completed30 · 81%
Unknown status5 · 14%
Withdrawn1 · 3%
Terminated1 · 3%

Trial Activity

37 trials

Dose Range Evaluation of Norovirus Challenge Pool (GII.4, CIN-1)
Completed··Phase 1·NCT01435811·60 enrolled
Administration of Virus-Specific Cytotoxic T-Lymphocytes
Completed··Phase 1·NCT00590083·14 enrolled
Multivirus-specific Cytotoxic T Lymphocytes (mCTL)
Completed··Phase 1·NCT02510404·1 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)